PatientsVille.com Logo

PatientsVille

Glakay Side Effects

Common Glakay Side Effects


The most commonly reported Glakay side effects (click to view or check a box to report):

Pyrexia (6)
Pneumonia (5)
White Blood Cell Count Decreased (4)
Septic Shock (3)
Hypertension (3)
Cough (3)
Chest Pain (2)
Henoch-schonlein Purpura (2)
Aspartate Aminotransferase Increased (2)
Erythema Multiforme (2)
Hepatic Function Abnormal (2)
Decreased Appetite (2)
Chills (2)
Platelet Count Decreased (2)
Palmar-plantar Erythrodysaesthesia Syndrome (2)
Multi-organ Failure (2)
Pancytopenia (2)
Rash (2)
Renal Failure (2)
Serum Ferritin Increased (2)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Glakay Side Effects Reported to FDA

The following Glakay reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Glakay on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Febrile Neutropenia, Hypertension, Platelet Count Decreased, White Blood Cell Count Decreased, Serum Ferritin Increased, Neutrophil Count Decreased
This is a report of a male patient (weight: NA) from JAPAN, suffering from the following symptoms/conditions: NA, who was treated with Glakay (dosage: 45 Milligram, start time: Jun 09, 2011), combined with:
  • Cefmetazole Sodium
  • Vidaza (75 Milligram/sq. Meter)
  • Vidaza (75 Milligram/sq. Meter)
  • Exjade
  • Decadron (4 Milligram)
  • Decadron (4 Milligram)
  • Decadron (4 Milligram)
  • Kytril (2 Milligram)
and developed a serious reaction and side effect(s). The consumer presented with:
  • Febrile Neutropenia
  • Hypertension
  • Platelet Count Decreased
  • White Blood Cell Count Decreased
  • Serum Ferritin Increased
  • Neutrophil Count Decreased
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Glakay treatment in male patients, resulting in febrile neutropenia side effect. The patient was hospitalized.

Decreased Appetite, Nasopharyngitis, Somnolence
This report suggests a potential Glakay Decreased Appetite, Nasopharyngitis, Somnolence side effect(s) that can have serious consequences. A 91-year-old female patient (weight: NA) from JAPAN was diagnosed with the following symptoms/conditions: osteoporosis,oedema peripheral,constipation and used Glakay (dosage: NA) starting Jun 14, 2011. Soon after starting Glakay the patient began experiencing various side effects, including:
  • Decreased Appetite
  • Nasopharyngitis
  • Somnolence
Drugs used concurrently:
  • Lasix
  • Kamag G
  • Menatetrenone
  • Bisolvon
  • Rabeprazole Sodium
  • Livalo
  • Galantamine Hydrobromide
  • Rocaltrol
The patient was hospitalized. Although Glakay demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as decreased appetite, may still occur.

Renal Failure, Respiratory Failure, Septic Shock, Multi-organ Failure
This Renal Failure, Respiratory Failure, Septic Shock, Multi-organ Failure problem was reported by a physician from JAPAN. A male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On Aug 20, 2011 this consumer started treatment with Glakay (dosage: 15 Mg, Tid). The following drugs were being taken at the same time:
  • Asacol (Unk)
  • Famotidine (20 Mg, Uid/qd)
  • Miya Bm (2 Df, Tid)
  • Prednisolone (6.25 Mg, Bid)
  • Prograf (3 Mg, Bid)
  • Ferrous Citrate (2 Df, Uid/qd)
  • Loperamide Hcl (1 Mg, Uid/qd)
When commencing Glakay, the patient experienced the following unwanted symptoms/side effects:
  • Renal Failure
  • Respiratory Failure
  • Septic Shock
  • Multi-organ Failure
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as renal failure, may become evident only after a product is in use by the general population.

Pancytopenia
This is a report of a female patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: NA and was treated with Glakay (dosage: NA) starting Sep 07, 2011. Concurrently used drugs:
  • Fosrenol
  • Mircera
  • Cinacalcet Hydrochloride
  • Rabeprazole Sodium
  • Urso 250
  • Risumic (In Front Of Hd)
  • Wasser V
  • Lac-b
Soon after that, the consumer experienced the following side effects:
  • Pancytopenia
The patient was hospitalized. This opens a possibility that Glakay treatment could cause the above reactions, including pancytopenia, and some female subjects may be more susceptible.


Sepsis, Epistaxis, Cellulitis, Myelodysplastic Syndrome
A female patient (weight: NA) from JAPAN with the following symptoms/conditions: NA started Glakay treatment (dosage: NA) on Dec 01, 2011. Soon after starting Glakay treatment, the subject experienced various side effects, including:
  • Sepsis
  • Epistaxis
  • Cellulitis
  • Myelodysplastic Syndrome
Concurrently used drugs:
  • Alfarol
  • Pursennid
  • Magnesium Sulfate
  • Vidaza (75 Milligram/sq. Meter)
  • Vfend
  • Ciprofloxacin
  • Mucodyne
  • Vidaza (37.5 Milligram/sq. Meter)
The patient was hospitalized. This finding indicates that some female patients could be more vulnerable to Glakay.

Cerebral Haemorrhage, Fall, Speech Disorder
A female patient from JAPAN (weight: NA) experienced symptoms, such as: NA and was treated with Glakay(dosage: 45 Mg, Unk). The treatment was initiated on Jun 21, 2010. After that a consumer reported the following side effect(s):
  • Cerebral Haemorrhage
  • Fall
  • Speech Disorder
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Glakay efficacy:
  • Cephadol (75 Mg, Unk)
  • Platibit (1 Ug, Unk)
  • Amlodipine Besylate/valsartan (1 Df, Daily)
The patient was hospitalized and became disabled.

Septic Shock, Pneumonia, White Blood Cell Count Decreased
In this report, Glakay was administered for the following condition: myelodysplastic syndrome,prophylaxis,type 2 diabetes mellitus.A male consumer from JAPAN (weight: NA) started Glakay treatment (dosage: 45 Mg, Unk) on Jun 01, 2009.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Septic Shock
  • Pneumonia
  • White Blood Cell Count Decreased
A possible interaction with other drugs could have contributed to this reaction:
  • Diflucan
  • Amaryl (1 Mg, Unk)
  • Diflucan (200 Mg, Unk)
  • Exjade (1000 Mg, Daily)
  • Lasix (10 Mg, Unk)
  • Aldactone (12.5 Mg, Unk)
  • Red Blood Cells, Concentrated (2 Units (every Week))
The patient was hospitalized.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Glakay treatment could be related to the listed above side effect(s).

Inflammatory Marker Increased, Pyrexia, Liver Disorder
This is a report of the following Glakay side effect(s):
  • Inflammatory Marker Increased
  • Pyrexia
  • Liver Disorder
A 62-year-old male patient from JAPAN (weight: NA) presented with the following condition: NA and received a treatment with Glakay (dosage: Daily Dose 45 Mg) starting: Jun 16, 2011.The following concurrently used drugs could have generated interactions:
  • Nizatidine (Daily Dose 300 Mg)
  • Lamivudine (Daily Dose 100 Mg)
  • Amoban (Daily Dose 5 Mg)
  • Nexavar (400 Mg, Bid)
  • Aldactone (Daily Dose 50 Mg)
  • Acetaminophen (Daily Dose 400 Mg)
  • Lasix (Daily Dose 20 Mg)
  • Loxonin (Daily Dose 60 Mg)
The patient was hospitalized.This report suggests that a Glakay treatment could be associated with the listed above side effect(s).

Anaemia, Drowning, White Blood Cell Count Decreased, Mallory-weiss Syndrome, Hepatic Function Abnormal, Palmar-plantar Erythrodysaesthesia Syndrome, Hypertension
This Glakay report was submitted by a 65-year-old male consumer from JAPAN (weight: NA). The patient was diagnosed with: NA and Glakay was administered (dosage: Since Before Administration) starting: Sep 25, 2009. The consumer developed a set of symptoms:
  • Anaemia
  • Drowning
  • White Blood Cell Count Decreased
  • Mallory-weiss Syndrome
  • Hepatic Function Abnormal
  • Palmar-plantar Erythrodysaesthesia Syndrome
  • Hypertension
Other drugs used simultaneously:
  • Allopurinol (Since Before Administration)
  • Fentanyl
  • Lansoprazole (15 Mg (daily Dose), , Oral)
  • Nexavar
  • Uralyt (Since Before Administration)
  • Fentanyl (Since Before Administration, 2.1/3mg)
  • Oxinorm (Since Before Administration)
  • Fentanyl (Since Before Administration, 4.2/3mg)
Those unexpected symptoms could be linked to a Glakay treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Ileus Paralytic, Constipation, Dysuria
This is a report of a possible correlation between Glakay use and the following symptoms/side effect(s):
  • Ileus Paralytic
  • Constipation
  • Dysuria
which could contribute to an assessment of Glakay risk profile.A 64-year-old male consumer from JAPAN (weight: NA) was suffering from NA and was treated with Glakay (dosage: NA) starting May 16, 2011.Other concurrent medications:
  • Teleminsoft
  • Ondasetron
  • Vidaza (75 Milligram)
  • Alinamin-f
  • Vidaza (75 Milligram)
  • Magnesium Sulfate
  • Pantol
  • Primobolan
The patient was hospitalized.

White Blood Cell Count Decreased, Septic Shock, Pneumonia
A male patient from JAPAN (weight: NA) presented with the following symptoms: myelodysplastic syndrome,iron overload,type 2 diabetes mellitus and after a treatment with Glakay (dosage: 45 Mg, Unk) experienced the following side effect(s):
  • White Blood Cell Count Decreased
  • Septic Shock
  • Pneumonia
The treatment was started on Oct 30, 2007. Glakay was used in combination with the following drugs:
  • Exjade (100 Mg)
  • Amaryl (1 Mg, Unk)
  • Lasix (10 Mg, Unk)
  • Red Blood Cells, Concentrated (2 Units (every Week))
  • Aldactone (12.5 Mg, Unk)
  • Diflucan (200 Mg, Unk)
  • Diflucan
The patient was hospitalized.This report could alert potential Glakay consumers.

Aspartate Aminotransferase Increased, Erythema Multiforme, Lip Erosion, Blood Creatine Phosphokinase Increased, Pyrexia, Alanine Aminotransferase Increased, Thrombocytopenia, Blood Albumin Decreased, Haemorrhage
In this report, a 78-year-old male patient from JAPAN (weight: NA) was affected by a possible Glakay side effect.The patient was diagnosed with NA. After a treatment with Glakay (dosage: 45 Mg (daily Dose), , Oral, start date: Sep 21, 2009), the patient experienced the following side effect(s):
  • Aspartate Aminotransferase Increased
  • Erythema Multiforme
  • Lip Erosion
  • Blood Creatine Phosphokinase Increased
  • Pyrexia
  • Alanine Aminotransferase Increased
  • Thrombocytopenia
  • Blood Albumin Decreased
  • Haemorrhage
The following simultaneously used drugs could have led to this reaction:
  • Urso 250 (600 Mg (daily Dose), , Oral)
  • Rabeprazole Sodium (10 Mg (daily Dose), , Oral)
  • Uft (300 Mg (daily Dose), , Oral)
  • Adjust-a (80 Mg (daily Dose), , Oral)
  • Livact (12.45 G (daily Dose), , Oral)
  • Falkamin (12.45 G (daily Dose), , Oral)
  • Magnesium Sulfate (1980 Mg (daily Dose), , Oral)
  • Nexavar
The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Glakay treatment.

Neoplasm Malignant, Pneumonia, Pruritus, Gamma-glutamyltransferase Increased, Pancytopenia, Oral Pain, Serum Ferritin Increased, Toxic Epidermal Necrolysis, Erythema Multiforme
This is a report of a female patient from JAPAN (weight: NA), who used Glakay (dosage: 45 Mg) for a treatment of myelodysplastic syndrome. After starting a treatment on Sep 01, 2006, the patient experienced the following side effect(s):
  • Neoplasm Malignant
  • Pneumonia
  • Pruritus
  • Gamma-glutamyltransferase Increased
  • Pancytopenia
  • Oral Pain
  • Serum Ferritin Increased
  • Toxic Epidermal Necrolysis
  • Erythema Multiforme
The following drugs could possibly have interacted with the Glakay treatment
  • Primobolan (Unk)
  • Exjade (1000 Mg, Qd)
  • Red Blood Cells (2 U, Unk)
The patient was hospitalized.Taken together, these observations suggest that a Glakay treatment could be related to side effect(s), such as Neoplasm Malignant, Pneumonia, Pruritus, Gamma-glutamyltransferase Increased, Pancytopenia, Oral Pain, Serum Ferritin Increased, Toxic Epidermal Necrolysis, Erythema Multiforme.

Bronchitis, Bacterial Infection, Dehydration, Pyrexia, Multi-organ Failure, Cough, Blood Creatinine Increased, Renal Failure
This bronchitis side effect was reported by a physician from JAPAN. A female patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Glakay (dosage: 45 Mg, Unk), which was started on Nov 13, 2009. Concurrently used drugs:
  • Exjade (500 Mg, Daily)
  • Neoral (100 Mg, Daily)
  • Desferal (500 Mg)
  • Neutrogin (2.50 Ug)
  • Clarithromycin (400 Mg)
  • Exjade (500 Mg Daily)
  • Neoral (75 Mg, Daily)
When starting to take Glakay the consumer reported the following symptoms:
  • Bronchitis
  • Bacterial Infection
  • Dehydration
  • Pyrexia
  • Multi-organ Failure
  • Cough
  • Blood Creatinine Increased
  • Renal Failure
The patient was hospitalized. These side effects may potentially be related to Glakay.

Platelet Count Decreased, Haematocrit Decreased, Vomiting, Red Blood Cell Count Decreased, Haemoglobin Decreased, Nausea
This is a Glakay side effect report of a female patient (weight:NA) from JAPAN, suffering from the following symptoms/conditions: prophylaxis, who was treated with Glakay (dosage:45 Mg, Unk, start time: Mar 28, 2009), combined with:
  • Red Blood Cells, Concentrated (02 Units Each Time)
  • Nasanyl (02 Df, Unk)
  • Exjade (1000 Mg Daily)
  • Takepron (15 Mg, Unk)
  • Adona (90 Mg, Unk)
  • Alfarol (03 Df, Unk)
  • Blood Transfusion, Auxiliary Products (Unk)
, and developed a serious reaction and a platelet count decreased side effect. The patient presented with:
  • Platelet Count Decreased
  • Haematocrit Decreased
  • Vomiting
  • Red Blood Cell Count Decreased
  • Haemoglobin Decreased
  • Nausea
which developed after the beginning of treatment. This side effect report can indicate a possible existence of increased vulnerability to Glakay treatment in female patients suffering from prophylaxis, resulting in platelet count decreased.

Hypertension, Insomnia, Hepatic Function Abnormal, Pollakiuria, Pyrexia
This report suggests a potential Glakay hypertension side effect(s) that can have serious consequences. A male patient from JAPAN (weight:NA) was diagnosed with the following health condition(s): NA and used Glakay (dosage: Before Nexavar Administration) starting Jul 27, 2010. Soon after starting Glakay the patient began experiencing various side effects, including:
  • Hypertension
  • Insomnia
  • Hepatic Function Abnormal
  • Pollakiuria
  • Pyrexia
Drugs used concurrently:
  • Mevalotin (Before Nexavar Administration)
  • Lendormin (0.25 Mg (daily Dose), , Oral)
  • Ursodeoxycholic Acid
  • Flivas (25 Mg (daily Dose), , Oral)
  • Allelock (Before Nexavar Administration)
  • Livact (Before Nexavar Administration)
  • Nexavar
  • Tryptanol (10 Mg (daily Dose), , Oral)
Although Glakay demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as hypertension, may still occur.

Hypoglycaemia, Palmar-plantar Erythrodysaesthesia Syndrome, Decreased Appetite
This hypoglycaemia problem was reported by a physician from JAPAN. A female patient (weight: NA) was diagnosed with the following medical condition(s): osteoporosis,gastric ulcer,back pain,hypoalbuminaemia,diarrhoea.On Sep 03, 2009 a consumer started treatment with Glakay (dosage: Daily Dose 45 Mg). The following drugs/medications were being taken at the same time:
  • Gastrom (Daily Dose 3 G)
  • Celecoxib (Daily Dose 200 Mg)
  • Livact (Daily Dose 12.45 G)
  • Lacb-r (Daily Dose 3 G)
  • Omepral (Daily Dose 20 Mg)
  • Sorafenib (raf Kinase Inhibitor) (Daily Dose 800 Mg)
  • Lopemin (Daily Dose 2 Mg)
  • Tannalbin (Daily Dose 3 G)
When commencing Glakay, the patient experienced the following unwanted symptoms /side effects:
  • Hypoglycaemia
  • Palmar-plantar Erythrodysaesthesia Syndrome
  • Decreased Appetite
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as hypoglycaemia, may become evident only after a product is in use by the general population.

Chest Pain, Chills, Cough, Henoch-schonlein Purpura, Pneumonia, Pyrexia, Rash
This is a Glakay side effect report of a 65-year-old male patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: myelodysplastic syndrome and was treated with Glakay (dosage: NA) starting Jan 17, 2008. Concurrently used drugs:
  • Alfarol
  • Niflan
  • Neo-minophagen C
  • Loxonin
  • Exjade (1125 Mg, Qd)
Soon after that, the consumer experienced the following of symptoms:
  • Chest Pain
  • Chills
  • Cough
  • Henoch-schonlein Purpura
  • Pneumonia
  • Pyrexia
  • Rash
The patient was hospitalized. This opens a possibility that Glakay could cause chest pain and that some male patients may be more susceptible.

Chest Pain, Chills, Cough, Henoch-schonlein Purpura, Pneumonia, Pyrexia, Rash
A 65-year-old male patient (weight: NA) from JAPAN with the following symptoms: myelodysplastic syndrome started Glakay treatment (dosage: NA) on Jan 17, 2008. Soon after starting Glakay treatment, the consumer experienced several side effects, including:
  • Chest Pain
  • Chills
  • Cough
  • Henoch-schonlein Purpura
  • Pneumonia
  • Pyrexia
  • Rash
. Concurrently used drugs:
  • Alfarol
  • Niflan
  • Neo-minophagen C
  • Loxonin
  • Exjade (1125 Mg, Qd)
The patient was hospitalized. This finding indicates that some patients can be more vulnerable to developing Glakay side effects, such as chest pain.

Aspartate Aminotransferase Increased, Disease Recurrence, Gamma-glutamyltransferase Increased, Hepatitis C
This aspartate aminotransferase increased side effect was reported by a physician from . A 66-year-old female patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Glakay (dosage: 45 Mg, Unk), which was started on NS. Concurrently used drugs:
  • Urso 250 (600 Mg, Unk)
  • Cabagin-u (6 Df, Unk)
  • Diovan (40 Mg, Qd)
.When starting to take Glakay the consumer reported symptoms, such as:
  • Aspartate Aminotransferase Increased
  • Disease Recurrence
  • Gamma-glutamyltransferase Increased
  • Hepatitis C
These side effects may potentially be related to Glakay. The patient was hospitalized.



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Glakay Side Effects

    Did You Have a Glakay Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Glakay for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Glakay Safety Alerts, Active Ingredients, Usage Information

    More About Glakay

    Side Effects reported to FDA: 20

    Glakay safety alerts: No

    Reported deaths: 6

    Reported hospitalizations: 15

    Latest Glakay clinical trials

    Glakay Reviews

    No reviews, be a first to report a side effect via side effect reporting form